Steven Cohen Janux Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 395,875 shares of JANX stock, worth $19.4 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
395,875
Previous 136,430
190.17%
Holding current value
$19.4 Million
Previous $5.72 Million
214.68%
% of portfolio
0.05%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
166Shares Held
37.6MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$449 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$124 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$118 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$115 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$102 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.04B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...